Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04060862
Title A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Ipatasertib + Palbociclib

Fulvestrant + Palbociclib

Age Groups: adult | senior
Covered Countries USA | ITA | GBR | ESP | CAN | AUT | AUS


No variant requirements are available.